GlaxoSmithKline's Profits Surge Amid Strategic Expansions

GlaxoSmithKline Pharmaceuticals reported a significant rise in its consolidated net profit, achieving a 36% increase to Rs 263 crore during the March quarter, compared to Rs 194 crore in the previous year. The pharmaceutical giant's revenue from operations also saw an uptick, reaching Rs 974 crore for the quarter, as submitted in a regulatory filing.

For the fiscal year ending March 31, 2025, the company recorded a net profit of Rs 927 crore, a substantial climb from Rs 590 crore in FY24. Revenues surged to Rs 3,749 crore from Rs 3,454 crore in the preceding financial year, thanks to robust growth in their portfolios of general medicines, specialty drugs, and vaccines, according to MD Bhushan Akshikar.

Looking forward, GlaxoSmithKline Pharmaceuticals is preparing to enhance its oncology product line with the launch of Zejula and Jemperli, targeting ovarian and endometrial cancers, respectively. The board has proposed a final dividend of Rs 42 per share for the year, reflecting strong confidence in sustained future growth.

(With inputs from agencies.)